Search

everythinglearnresearchcommunity

for

Search:↓

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

An 18-year-old male is experiencing significant hair shedding, particularly from the back of his head, despite normal blood test results except for slightly low vitamin D. A dermatologist prescribed minoxidil for receding temples, but the cause of the shedding remains unclear.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

Nizoral 1% shampoo can be used continuously for hair loss, but it may cause dryness, which can be managed with conditioners. Some users combine it with other treatments like minoxidil and AHK-Cu for better results.

The user experienced side effects like heart palpitations, chest tightness, and fatigue from using 5% minoxidil foam once daily. They are considering switching to a 2% concentration due to lingering symptoms like lightheadedness and brain fog.

The conversation is about a group of people trying KX-826 for hair loss, with no serious side effects reported after 25 days of use. Some participants are experiencing less scalp itch and shedding, but it's too early for definitive results.

The conversation is about comparing the effectiveness of adenosine and minoxidil for treating hair loss. People are sharing their thoughts and experiences on which is better.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

The user has been taking 1mg of finasteride every other day for two months, experiencing improved hair quality but disrupted sleep. They are seeking advice on whether the sleep issues will improve with continued use or if they should stop the medication.

RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.

The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.

Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

A 22-year-old male with high estrogen levels is considering finasteride for hair loss but is concerned about potential side effects due to his hormone levels and family history of diabetes. Users suggest consulting a doctor, possibly an endocrinologist, and considering lifestyle changes like diet and exercise to address visceral fat and insulin resistance before starting treatment.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The user is using oral minoxidil and dutasteride for hair loss and observed changes in blood pressure after taking oral minoxidil. They experienced no visible symptoms from topical minoxidil, finasteride, or other treatments and are seeking feedback on whether these blood pressure changes are typical for oral minoxidil users.

An 18-year-old experiencing mild hair thinning is prescribed ketoconazole shampoo, clobetasol, and a solution with minoxidil, finasteride, and tretinoin. They are hesitant to start finasteride due to concerns about systemic absorption and its impact on facial hair development.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

User shared 7-month progress of hair loss treatment, using daily 1mg Fin, 2x Min, monthly micro-needling, and ketocoz shampoo. They advise focusing on haircare, diet, and mental health after establishing a routine.

The conversation discusses hair loss treatments, specifically using topical minoxidil, oral finasteride, ketoconazole, and derma stamping. Users share their experiences, with one noting improved scalp health and slight regrowth, while another considers switching treatments due to lack of progress.

The user is experiencing significant hair regrowth with 5 mg oral minoxidil and 1 mg finasteride but also side effects like eye puffiness and hypertrichosis. They are considering reducing the minoxidil dose to 2.5 mg to lessen side effects and are curious about caffeine serums for eye puffiness.

The conversation is about the effectiveness of ketoconazole shampoo for hair loss. The conclusion is that ketoconazole shampoo can help with dandruff and seborrheic dermatitis, but it is not a strong enough treatment to stop or regrow hair. It is recommended to use it as an adjunct treatment along with finasteride or dutasteride.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.

The safety of using oral minoxidil to treat hair loss and thinning, with studies showing mild side effects at low doses. It was suggested that people should consult a doctor or dermatologist before taking any type of medication for hair loss.

The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.